Tumor gene therapy developer rebrands, emerges with $30M from blue-chip investors

A transatlantic oncology outfit is entering 2023 with a new look, name, office space and $30 million to work with.

Akamis Bio — named after Akamas, one of the warriors inside Greek mythology’s Trojan horse — put word out on Thursday that it received $30 million in the form of...

Click to view original post